Hanley K, Wang J, Bourne P, Yang Q, Gao AC, Lyman G, Tang PLack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Hum Pathol 39: 386-392

Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.
Human Pathlogy (Impact Factor: 2.77). 04/2008; 39(3):386-92. DOI: 10.1016/j.humpath.2007.07.007
Source: PubMed


Androgen receptor has been implicated in the pathogenesis of breast carcinoma. In this study, we explored the potential role of androgen receptor in breast cancer by analyzing its expression using immunohistochemistry and its relationship with tumor progress (ductal carcinoma in situ [DCIS] versus invasive ductal carcinoma [IDC]); nuclear grades (high grade [HG] versus non-high grade); expression of estrogen receptor (ER), progesterone receptor (PR), HER-2; and 3 molecular classifications: cytokeratin classification, triple (ER/PR/HER-2) negative classification, and ER/HER-2 classification in 184 breast carcinomas. We found that (1) lack of androgen receptor expression was associated with HG-IDC and with basal subtypes of HG-IDC, suggesting androgen receptor may play an important role in preventing the invasive transformation in this subgroup of breast carcinoma. (2) HG-IDC and HG-DCIS more frequently expressed androgen receptor than ER (55%-93% for androgen receptor and 18%-30% for ER) and were frequently androgen receptor+/ER- (63% for HG-DCIS and 39% for HG-IDC), which made androgen receptor a possible therapeutic target. (3) One third of HG-IDC was negative for androgen receptor, ER, PR, and HER-2, suggesting that further studies are needed to identify other key molecules for targeted therapy. We purpose that androgen receptor should be routinely measured for breast cancer.

8 Reads
  • Source
    • ">10% Rakha et al, 2006 <ref type="bibr" target="#b46" coords="7;92.834;307.233;490.71000000000004;358.311">[44]</ref> 1726 282 (16.3%) 36 (12.7%) ≥1% Hu et al, 2011 [45] 1467 211 (14.3%) 78 (37%) ≥1% Loibl et al, 2011 [46] 673 111 (17%) 24 (21.6%) AR+*** Micello et al, 2010 [47] 226 135 (60%) 41 (30.3%) >10% Masuda et al, 2010 [48] 163 31 (20%) 6 (18%) Any positive staining Hanley et al, 2008 [49] 94 20 (21%) 5 (25%) >10% Thike et al, 2014 [50] 699 699 265 (38%) ≥1% Current study, 2014 400 509 (12.5%) 18 (36%) ≥1% "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Triple negative breast carcinomas (TNBC) do not benefit from hormonal or Herceptin therapies. In search of novel therapeutic targets for TNBC, interest is escalating in a subset of these tumors that are androgen receptor (AR) positive with potential benefit from anti-androgen therapy. Against this background, the frequency of AR expression alone and in combination with other markers and morphologic features was assessed to identify TNBC subtypes for targeted therapy. Methods: 400 consecutive invasive mammary carcinomas with known estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR) and HER2 status were selected for study. The frequency of AR positivity alone or in combination with other markers was recorded with specific attention to the morphology of AR+ TNBCs. Ki67 was evaluated in selected group of cases. ASCO/CAP guidelines were used for interpretation of the various biomarkers. Results: Of the 400 tumors, 32 (8%) carcinomas were quadruple negative (ER-, PR-, AR-, Her2-), while 50 tumors (12.5%) were triple negative (ER-, PR-, Her2-); 18 (36%) of the triple negative tumors were AR positive and 10 (55%) of these were classic apocrine carcinomas. Fourteen cases, all apocrine carcinomas, were AR and Her2 positive. All 32 QN carcinomas were poorly differentiated and they had the highest Ki67 labeling index. Conclusion: The relatively high proportion of AR+ tumors (36%) among the 50 triple negative carcinomas is an important finding in support of routine assessment of AR in at least all TNBCs and apocrine carcinomas as a potential target for therapy.
    American Journal of Cancer Research 07/2014; 4(4):353-68. · 4.17 Impact Factor
  • Source
    • "Epidemiologic studies showed that increased serum androgen level was associated with an increased risk for breast cancer in postmenopausal patients [17]. Hanley et al. investigated the potential role of AR in relation to breast tumor progression and showed that 93% of 43 high-grade ductal carcinoma in situ cases expressed AR, whereas only 55% of 44 high grade invasive ductal carcinomas showed AR expression showing a grade dependent upregulation [18]. Thus several growth factor pathways and steroid receptors play various roles in cancer progression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Growth factor signaling plays a key role in the growth and development of breast. Aberrant expression and activation of growth factors like insulin like growth factor-I (IGF-I) and epidermal growth factor (EGF) and their downstream sig-naling has been implicated in breast cancer. The deregulation of growth factor signaling is associated with increased proliferation and cell survival, decreased apoptosis, invasion, angiogenesis and metastasis. The aim of the present study is to survey the different signaling molecules involved in the IGF and EGF signaling pathways, and to find if there are any relationship between breast cancer and their levels and activation. Thirty-nine samples of breast cancer tissues (24 Grade II and 15 Grade III tumours) and sixteen normal breast tissue samples were collected. The expression of the re-ceptors and signaling molecules were investigated using Western blot. IGF-IRβ, AR, pAkt, IKK-α and p38 are upregu-lated in cancer tissues in a grade depended manner. Further, Akt and β-catenin were also upregulated in cancer samples. Correlation analysis of signaling molecules revealed a disruption in their expression in cancer tissues. The present study shows that various signaling molecules are upregulated or activated in cancer tissues involving IGF-IR and Akt path-way. The expression of signaling molecules in the cancer tissues were deregulated when compared to the control sam-ples. Thus, flawed expression and over activation of Akt pathway is seen in the breast cancer tissues.
    Journal of Cancer Therapy 06/2013; 4(07). DOI:10.4236/jct.2013.47A005
  • Source
    • "In the same analysis, ER expression decreased from 100% to 8% in DCIS and to 9.5% in invasive carcinoma, with increasing tumor grade. These findings have been validated by another independent report [54]. In addition, it has been shown that, albeit at a low percentage (25%), AR is the sole sex hormone receptor expressed in distant breast cancer metastases [52]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer occurs at a high frequency in women and, given this fact, a primary focus of breast cancer research has been the study of estrogen receptor α (ER) signaling. However, androgens are known to play a role in normal breast physiology and therefore androgen receptor (AR) signaling is becoming increasingly recognized as an important contributor towards breast carcinogenesis. Moreover, the high frequency of AR expression in breast cancer makes it an attractive therapeutic target, but the ability to exploit AR for therapy has been difficult. Here we review the historical use of androgen/anti-androgen therapies in breast cancer, the challenges of accurately modeling nuclear hormone receptor signaling in vitro, and the presence and prognostic significance of AR in breast cancer.
    American Journal of Cancer Research 08/2012; 2(4):434-45. · 4.17 Impact Factor
Show more